By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Paul Berg will retire from his post on Affymetrix's board of directors in May, the company said this week. Berg has served on the company's board since 1993.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.
An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.
In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.
The new Riken president outlines some of his plans for the institute.